

( )

//

//

\*

*PH*

*Infant star 500*

/

%

*F102*

% ( )%    % ( )%    % ( )%    % ( )%

( )%    ( )%    ( )%

( )%

*NICU*

:

Fujiwara .( )

Avery

( )

(RDS)

.( )

/ PH  
Infant star 500

FiO<sub>2</sub>

.( ) RDS

.( )

( )

( )

.( )

RDS

NICU

(% )

(% )

(% )

(% )

( )

NICU

(% )

(% )

(% )

Gortner

Kendig

(rescue

RDS (Prophylaxis)

therapy)

RDS

(PIE)

Verhagen Gortner

% /

Kendig

%

%

( ) Kendig

% %

% / ( ) Gortner

PIE

BPD

% / ( ) Gorbe

PIE % /

Curosurf

%

( ) Navas

BPD

% /

(% )

% / ( ) Lamboley

% ( ) Verhagen

(

Gortner Kendig

(

Navas Kendig

Gortner

BPD

(% / )

( BPD )

( ) Kendig

%

NICU

% / ( ) Gortner

%

Verhagen

% / ( ) Gorbe

BPD

BPD

% ( )

---

## REFERENCES

---

1. Avery ME, Mead J. Surface Properties in relation to atelectasis and hyalin membrane disease. *Am J Dis Child* 1959; 97 : 517-23.
2. Shapiro DL. Future of surfactant replacement therapy. In: Shapiro DL, Notter RH, eds. New York , Ny : Alan R. Liss Inc. 1989. pp:305-9.
3. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyalin membrane disease . *Lancet* 1980;1(8159):55-9.
4. Halliday HL. Natural VS synthetic Surfactant in neonatal respiratory distress Syndrome. *Drugs* 1996;51(2):226-37.
5. Robertson B, Halliday HL. Principles of surfactant replacement. *Biochim Biophys Acta* 1998;1408(2-3):346-61.
6. Soll RF. Synthetic Surfactant for respiratory distress Syndrome in preterm infants (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2004. Chichester: John Wiley & Sons, LTd.
7. Verhagen AA, Keli SO, van der Meulen GN, Wiersma H, Arias M, Angelista IR, et al. Surfactant treatment in premature infants with respiratory distress syndrome in Curacao. *West Indian Med J*;50(2):117-22.
8. Görbe E, Jeager J, Kohalmi B, Patkós P, Cziniel M, Sassi L.. The Combine effect of prenatal steroid prophylaxis, neonatal Surfactant therapy and reduction of risk of complication from infants. *Orv Hetil* 2004;145(23):1227-32.
9. Genzel-Boroviczény O, MacWilliams S, Von Poblitzki M, Zoppelli L. Mortality and major morbidity in premature infants less than 31 weeks gestational age in the decade after introduction of surfactant. *Acta Obstet Gynecol Sand* 2006 ; 85(1) : 68-73.
10. American Academy of pediatrics committee of Fetus and Newborn. Surfactant replacement therapy for respiratory distress Syndrome. *Pediatrics* 1991;87:946-7.
11. Jobe AH. Pulmonary Surfactant therapy. *N Engl J Med* 1993 :328(12):861-8.
12. Bancalari E, del Moral T. Bronchopulmonary dysplasia and Surfactant. *Biol Neonate* 2001;80 suppl 1:7 -13.
13. Raju TNK, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a Meta analysis. *J Pediatr Res* 1993;123:603-10.
14. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al. High frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. *N Engl J Med* 2002;347(9):633-42.
15. Kendig JW, Ryan RM, Sinkin RA, Maniscalco WM, Notter RH, Guillet R, et al. Comparision of two strategies for Surfactant prophylaxis in very premature infants: A multicenter randomized trial. *Pediatrics* 1998; 101(6):1006-12.

- 
16. Gortner L, Wauer RR, Hammer H, Stock GJ, Heitmann F, Reiter HL, et al. Early versus late Surfactant treatment in preterm infants of 27 to 32 weeks Gestational age: A Multicenter Controlled Clinical Trial. *Pediatrics* 1998;102(5):1153-9.
  17. Navas Serrano VM, Cuevas García MA, Vila Alvarez JA, Martínez Fernández V, Morcillo Sopena F, Valls I Soler A. Prophylaxis and Treatment of respiratory distress Syndrome with different surfactant. *An Esp Pediatr* 2002;56(1):40-4.
  18. Verhagen AA, van der Meulen GN, Wiersma HE, Keli SO, Angelista IR, Muskiet FD, et al. Respiratory distress Syndrome in curacao. Conventional versus surfactant treatment . *West Indian Med J* 2002;51(2):68-73.
  19. Lamboley-Gilmert G, Lacaze Masmonteil T, Neonatologists of the curosurf post marketing French study. The short term out come of a large cohort of very preterm infants treated with poractant alfa (curosurf) for respiratory distress syndrome. A Postmarketing phase IV study. *Paediatr Drugs* 2003;5(9):639-45.